Heidelberg Pharma will Present at German Equity Forum and Provides Update on Partner Activities for its Legacy Assets
- RedHill Biopharma plans Phase II/III trial with upamostat in COVID-19
- Telix Pharmaceuticals enters into strategic license and commercial partnership for China with radio-labelled antibody girentuximab
Heidelberg Pharma AG today announced that it will give a presentation at the German Equity Forum (Eigenkapitalforum, EKF) and provided an update on recent news from its licensing partners.